ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Volume : 26 Issue : 1 Year : 2022
Quick Search



The Anatolian Journal of Cardiology NLRP3 inflammasome as a novel therapeutic target for heart failure [Anatol J Cardiol]
Anatol J Cardiol. 2022; 26(1): 15-22 | DOI: 10.5152/AnatolJCardiol.2021.580

NLRP3 inflammasome as a novel therapeutic target for heart failure

Shuangcui Wang1, Jiaqi Zhang1, Yuli Wang1, Xijuan Jiang1, Maojuan Guo1, Zhen Yang2
1Department of Integrative Medicine, Tianjin University of Traditional Chinese Medicine; Tianjin-China
2Department of Chinese Medicine, Tianjin University of Traditional Chinese Medicine; Tianjin-China

Heart failure (HF) is a leading cause of mortality worldwide. The pathogenesis of HF is complex and has not yet been fully elucidated, which has slowed drug development and long-term treatments. Inflammasome-mediated responses occur during the progression of HF. It has been reported that energy metabolism and metabolites of intestinal flora are also involved in the process of HF, and they interact with each other to promote the progression of HF. NLR family pyrin domain containing 3 (NLRP3) inflammasome may be a key target in the relationship between inflammation-mediated energy metabolism and metabolites of intestinal flora. Elucidating the relationship among the above three factors may help to identify new molecular targets for the prevention and treatment of HF and ultimately affect the course of HF. In this study, we systematically summarize evidence regarding the relationship among NLRP3 inflammasome, energy metabolism, intestinal microflora metabolites, and inflammation, as well as highlight advantages of NLRP3 inflammasome in treating HF.

Keywords: heart failure, inflammation, NLRP3, metabolism, flora

Shuangcui Wang, Jiaqi Zhang, Yuli Wang, Xijuan Jiang, Maojuan Guo, Zhen Yang. NLRP3 inflammasome as a novel therapeutic target for heart failure. Anatol J Cardiol. 2022; 26(1): 15-22

Corresponding Author: Maojuan Guo
Manuscript Language: English